Clinical Trial on the Safety and Tolerability of Personalized Cancer Vaccines Using Human Platelet Lysate-Induced Antigen-Presenting Cells.
antigen-presenting cells
enzyme-linked immunosorbent assay
in silico prediction
memory T cells
personalized cancer vaccine
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Jul 2023
14 Jul 2023
Historique:
received:
27
05
2023
revised:
27
06
2023
accepted:
11
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Research and development of personalized cancer vaccines as precision medicine are ongoing. We predicted human leukocyte antigen (HLA)-compatible cancer antigen candidate peptides based on patient-specific cancer genomic profiles and performed a Phase I clinical trial for the safety and tolerability of cancer vaccines with human platelet lysate-induced antigen-presenting cells (HPL-APCs) from peripheral monocytes. Among the five enrolled patients, two patients completed six doses per course (2-3 × 10
Identifiants
pubmed: 37509288
pii: cancers15143627
doi: 10.3390/cancers15143627
pmc: PMC10377585
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Vaccines (Basel). 2019 Sep 19;7(3):
pubmed: 31546936
Lancet Oncol. 2014 Jun;15(7):e257-67
pubmed: 24872109
Acta Pharmacol Sin. 2020 Nov;42(11):1725-1741
pubmed: 33574569
Front Oncol. 2021 Jul 26;11:701777
pubmed: 34381724
Oncoimmunology. 2021 Jun 27;10(1):1935557
pubmed: 34239773
Cancer Res. 2012 May 15;72(10):2457-67
pubmed: 22589270
Genes Cells. 2021 May;26(5):313-327
pubmed: 33662167
Vaccines (Basel). 2020 Dec 24;9(1):
pubmed: 33374342
J Exp Med. 2006 Jul 10;203(7):1701-11
pubmed: 16818678
Nat Commun. 2022 Sep 10;13(1):5333
pubmed: 36088370
Nat Rev Drug Discov. 2020 Sep;19(9):635-652
pubmed: 32764681
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Nat Commun. 2019 Jan 25;10(1):449
pubmed: 30683863
Nat Rev Clin Oncol. 2021 Apr;18(4):215-229
pubmed: 33473220
Clin Cancer Res. 2014 Aug 15;20(16):4228-39
pubmed: 25056373
Sci Rep. 2017 Feb 13;7:42145
pubmed: 28191816
Blood. 2002 Sep 1;100(5):1734-41
pubmed: 12176895
Vaccines (Basel). 2015 Dec 11;3(4):1004-18
pubmed: 26690485
PLoS One. 2014 Mar 19;9(3):e92380
pubmed: 24647761
Clin Exp Immunol. 2013 Oct;174(1):179-91
pubmed: 23750604
Hum Vaccin Immunother. 2014;10(11):3175-8
pubmed: 25483658
Nat Med. 2017 Jan 6;23(1):18-27
pubmed: 28060797
PLoS One. 2020 Feb 25;15(2):e0229461
pubmed: 32097435
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Int J Mol Sci. 2022 Oct 12;23(20):
pubmed: 36293034
Nucleic Acids Res. 2020 Jul 2;48(W1):W449-W454
pubmed: 32406916
J Exp Med. 1997 Jun 16;185(12):2133-41
pubmed: 9182685
Nat Cancer. 2022 Aug;3(8):911-926
pubmed: 35999309
Immunity. 2013 Jul 25;39(1):38-48
pubmed: 23890062
Sci Rep. 2015 Feb 23;5:8535
pubmed: 25705018
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282837
Trends Cancer. 2018 Feb;4(2):119-137
pubmed: 29458962
Mol Ther. 2021 Feb 3;29(2):555-570
pubmed: 33038322
Front Immunol. 2023 Mar 17;14:1157537
pubmed: 37006306
Biomedicines. 2015 Dec 04;3(4):304-315
pubmed: 28536414
Signal Transduct Target Ther. 2021 Jan 20;6(1):26
pubmed: 33473101
Anticancer Res. 2018 Apr;38(4):2217-2225
pubmed: 29599342